Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 5/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19555684 | 0.98 | NOTUM (0.42) | NOTUMEPHX2LMNAALDH1A1GRM5 | |
| SCHEMBL92807 | 0.81 | EPHX2 (0.42) | EPHX2LMNAALDH1A1GRM5IGF1R | |
| SCHEMBL2306096 | 0.79 | LMNA (0.45) | NOTUMEPHX2LMNAALDH1A1GRM5 | |
| SCHEMBL4158787 | 0.79 | NOTUM (0.43) | NOTUMEPHX2CYP2E1CYP2A6CYP2C9 | |
| SCHEMBL9386575 | 0.79 | EPHX2 (0.41) | EPHX2LMNAALDH1A1GRM5IGF1R | |
| SCHEMBL745934 | 0.79 | ALDH1A1 (0.49) | EPHX2LMNAALDH1A1GRM5IGF1R | |
| SCHEMBL1106840 | 0.79 | ALDH1A1 (0.43) | EPHX2LMNAALDH1A1GRM5RAB9A | |
| SCHEMBL18884429 | 0.79 | EPHX2 (0.48) | EPHX2LMNAALDH1A1IGF1RRAB9A | |
| SCHEMBL9548280 | 0.78 | NOTUM (0.40) | NOTUMEPHX2LMNAALDH1A1CYP2E1 | |
| SCHEMBL4119886 | 0.78 | RAB9A (0.47) | EPHX2LMNAALDH1A1GRM5IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2613785-B1 | HETEROARYLMETHYL AMIDES | HOFFMANN LA ROCHE (CH) | 2015-07-29 | — | — | EP | claimed |
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | claimed |
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2014-07-10 | — | — | US | claimed |
| US-8729105-B2 | Heteroarylmethyl amides | HOFFMANN LA-ROCHE INC. (US) | 2014-05-20 | — | — | US | claimed |
| EP-2613785-A1 | HETEROARYLMETHYL AMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-17 | — | — | EP | claimed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | claimed |
| EP-4537901-A2 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | F. Hoffmann-La Roche AG (CH) | 2025-04-16 | — | — | EP | disclosed |
| EP-3826679-B1 | ABCA1-INDUCING COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | HOFFMANN LA ROCHE (CH) | 2024-11-27 | — | — | EP | disclosed |
| US-20240325372-A1 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | HOFFMANN LA ROCHE (US) | 2024-10-03 | — | — | US | disclosed |
| CN-112469442-B | Compounds for treating kidney disorders | 豪夫迈·罗氏有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117736141-A | Compounds for treating kidney disorders | 豪夫迈·罗氏有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | ALKAHEST, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20210275514-A1 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | HOFFMANN LA ROCHE (US) | 2021-09-09 | — | — | US | disclosed |
| EP-2010535-A1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| US-20080249079-A1 | N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine; IGF1R modulators; Abl mutant inhibitors; antiproliferative agents; to modulate cellular activities like differentiation, programmed cell death, migration, chemoinvas | EXELIXIS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249079-A1 | N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine; IGF1R modulators; Abl mutant inhibitors; antiproliferative agents; to modulate cellular activities like differentiation, programmed cell death, migration, chemoinvas | EXELIXIS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
| WO-2007120098-A1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
| US-20050054638-A1 | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-i) | ASTRAZENECA AB | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | NOTUM 391/4885EPHX2 1002/4885LMNA 886/4885 |
| US-20080249079-A1 | N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine; IGF1R modulators; Abl mutant inhibitors; antiproliferative agents; to modulate cellular activities like differentiation, programmed cell death, migration, chemoinvas | IGF1R, INSR, ERBB3 | NOTUM 4856/4885EPHX2 3742/4885LMNA 2618/4885 |
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | CCR3, CCR1, CCR4 | NOTUM 4588/4885EPHX2 607/4885LMNA 1709/4885 |
| US-20210275514-A1 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | GLS, ATP6V1B1, PLAAT2 | NOTUM 3652/4885EPHX2 2843/4885LMNA 1133/4885 |
| US-20240325372-A1 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | GLS, ATP6V1B1, DGKB | NOTUM 3382/4885EPHX2 3472/4885LMNA 582/4885 |
| US-20050054638-A1 | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-i) | IGF1R, IGFBP1, INSR | NOTUM 4781/4885EPHX2 4278/4885LMNA 3680/4885 |
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | NOTUM 1823/4885EPHX2 1438/4885LMNA 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.